Great news.
Added with the propriety formulation of Presendin and Orphan Drug Designation, the IP protection is formidable and befitting of a quality biotech.
It appears the EU patent was granted only for ICP related to IIH whereas the US office was more flexible in allowing conditions related raised ICP including TBI, Hydrocephalus etc.
Doesn’t seem to matter though. Once Invex takes Presendin to market for IIH, it’ll be bought out by Big Pharma before they expand to other large scale trials in other indications.
- Forums
- ASX - By Stock
- Ann: Invex Granted Key European Patent for Exenatide
IXC
invex therapeutics ltd
Add to My Watchlist
0.00%
!
9.1¢

Great news.Added with the propriety formulation of Presendin and...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
9.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $6.839M |
Open | High | Low | Value | Volume |
9.1¢ | 9.1¢ | 9.1¢ | $140 | 1.535K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 41290 | 8.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
9.7¢ | 9000 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 41290 | 0.088 |
1 | 42086 | 0.083 |
1 | 40000 | 0.075 |
1 | 14285 | 0.070 |
1 | 16666 | 0.060 |
Price($) | Vol. | No. |
---|---|---|
0.097 | 9000 | 1 |
0.099 | 59180 | 2 |
0.100 | 2750 | 1 |
0.105 | 50000 | 1 |
0.150 | 713 | 1 |
Last trade - 12.30pm 08/07/2025 (20 minute delay) ? |
Featured News
IXC (ASX) Chart |